| Report ID | 278888 |
| Drug Identification Number | 02558238 |
| Brand name | YESAFILI |
| Common or Proper name | Aflibercept |
| Company Name | BIOSIMILAR COLLABORATIONS IRELAND LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | AFLIBERCEPT |
| Strength(s) | 2MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVITREAL |
| Packaging size | Pre-filled Syringe |
| ATC code | S01LA |
| ATC description | OCULAR VASCULAR DISORDER AGENTS |
| Reason for shortage | Other (Please describe in comments) |
| Anticipated start date | |
| Actual start date | 2026-02-19 |
| Estimated end date | 2026-03-16 |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2026-03-10 |
| Company comments | Delay due to disruption in drug product release. Yesafili vials 2 mg/0.05 mL (DIN 02535858) is available. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | GRANGE PARADE, BALDOYLE INDUSTRIAL ESTATE, DUBLIN 13 DUBLIN, -- IRELAND D13R20R |
| Company contact information |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2026-03-10 | French | Compare |
| v3 | 2026-03-10 | English | Compare |
| v2 | 2026-02-24 | French | Compare |
| v1 | 2026-02-24 | English | Compare |
Showing 1 to 4 of 4